Calliditas Therapeutics AB (publ) (0A5R.L)
| Previous close | 103.55 |
| Open | 104.20 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 103.40 - 105.92 |
| 52-week range | 81.30 - 141.89 |
| Volume | |
| Avg. volume | 17,618 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
- Insider Monkey
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript February 21, 2024 Calliditas Therapeutics AB (publ) isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Calliditas Therapeutics Q4 2023 Report. For the first part of the conference […]
- Zacks
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
